Anzeige
Mehr »
Dienstag, 26.08.2025 - Börsentäglich über 12.000 News
Mega-Deal in Kanada: Katapultiert sich diese Aktie jetzt in die Top-Liga der Explorer?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
238 Leser
Artikel bewerten:
(1)

Assistek Inc: assisTek Unveils Cutting-Edge Technology Platform to Elevate Clinical Trial Data Collection

Transforming Clinical Research: assisTek's Innovative New Platform Raises the Bar for Data Collection and Patient Impact

DOYLESTOWN, PA / ACCESSWIRE / March 26, 2024 / assisTek, a leading innovator in e-clinical solutions for clinical research, proudly unveils its latest breakthrough: an innovative eCOA platform designed to provide a state-of-the-art user experience in order to enhance the ease of clinical trial data collection. Through the cornerstones of mobile and creative software technologies, assisTek's latest data collection platform aims to shape a new technological world in the space of clinical trial data collection, affecting not only the efficiency and security of data collection but also enhancing the experiences of both researchers and patients specific to the process.

Key features of assisTek's new platform include:

Single Sign-On (SSO) for Enhanced Security and Seamlessness:

The eCOA platform now offers seamless Single Sign-On integration, bolstering security measures while simplifying user authentication processes. With SSO, users can access multiple systems and applications with just one set of login credentials, reducing the risk of unauthorized access and enhancing the overall user experience.

Remote Provisioning for Streamlined Operations and Flexibility:

assisTek's eCOA platform introduces remote provisioning capabilities, enabling researchers to efficiently manage and distribute study materials to participants regardless of their location. This feature streamlines operations, eliminates logistical challenges, and facilitates timely data collection, leading to more efficient clinical trial workflows.

Proprietary Operating System (Prop OS) for Enhanced Performance and Security:

The new platform is powered by assisTek's proprietary operating system, engineered to deliver unmatched performance, reliability, and security. Built upon years of research and development, this advanced operating system ensures seamless integration, optimal data protection, and unparalleled stability, meeting the rigorous demands of modern clinical trials.

"Our new platform marks a turning point in how we collect clinical trial data," said Jon Osifchin, Senior Vice President of Technology at assisTek. "By blending advanced technology with our passion for innovation, we're giving researchers the tools they need to collect top-notch data more efficiently, securely and effectively than ever before. This isn't just about numbers; it's about making real strides in medical research and, ultimately, helping patients."

assisTek's new eCOA platform is now available to researchers and pharmaceutical companies seeking to optimize their clinical trial processes and accelerate the development of life-changing therapies. With offices strategically located in Doylestown, Pennsylvania; Scottsdale, Arizona; Austin, Texas; and internationally in Copenhagen, Denmark, assisTek reaffirms its dedication to serving clients across the globe with unparalleled service and support.

For more information about assisTek's groundbreaking platform, visit www.assistek.com.

About assisTek:

assisTek is a leading provider of technology solutions for clinical trials, specializing in electronic Clinical Outcomes Assessment (eCOA) platforms. With a focus on harnessing the latest advancements in technology to optimize data collection processes, assisTek delivers highly scalable, customizable solutions powered by a proven, cloud-based platform. Complemented by executives with 25+ years in the industry, experienced project managers and dedicated customer support teams, assisTek provides tailored consultation and boutique service to clients worldwide.

Contact Information

Mackenzie Gastineau
www.assistek.com
info@assistek.com

SOURCE: assisTek, Inc.

.

View the original press release on newswire.com.

© 2024 ACCESS Newswire
Zeitenwende! 3 Uranaktien vor der Neubewertung
Ende Mai leitete US-Präsident Donald Trump mit der Unterzeichnung mehrerer Dekrete eine weitreichende Wende in der amerikanischen Energiepolitik ein. Im Fokus: der beschleunigte Ausbau der Kernenergie.

Mit einem umfassenden Maßnahmenpaket sollen Genehmigungsprozesse reformiert, kleinere Reaktoren gefördert und der Anteil von Atomstrom in den USA massiv gesteigert werden. Auslöser ist der explodierende Energiebedarf durch KI-Rechenzentren, der eine stabile, CO₂-arme Grundlastversorgung zwingend notwendig macht.

In unserem kostenlosen Spezialreport erfahren Sie, welche 3 Unternehmen jetzt im Zentrum dieser energiepolitischen Neuausrichtung stehen, und wer vom kommenden Boom der Nuklearindustrie besonders profitieren könnte.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche Aktien besonders von der Energiewende in den USA profitieren dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.